The boundaries between humans and machines are blurring at an unprecedented rate, with the latest innovation in medical technology pushing the limits of what we consider "normal." Electronic implants are now being used to restore sight to those who have suffered from age-related macular degeneration, a disease that affects around 600,000 people in the UK alone.
The new treatment involves surgically implanting a microchip into the retina, which functions as a pattern converter. A camera in a pair of glasses sends visual information to the chip via infrared light, and the chip converts it back into electrical signals that are detected by the retina. The result is astonishing – 84% of patients in a recent trial were able to read letters and numbers with the device, equivalent to an average improvement of about five lines on a standard eye-test chart.
But this is not just a one-off success story; the potential applications of electronic implants are far-reaching. Devices that can read brainwaves are allowing paralysed people to type, while prosthetics currently in trials are controlled by sensors placed on muscles and nerves remaining after amputation, providing users with a sense of touch and proprioception.
The future may seem like science fiction, but it's already here – or at least, it's being developed. Elon Musk's Neuralink venture has taken the lead in direct brain-computer interface technology, implanting a chip into a volunteer's brain to allow basic commands to be sent to a computer.
However, as with any new medical technology, there are risks involved. Adverse events were reported during the macular degeneration trial, including retinal damage requiring further surgery. And even with direct brain implants, there's still a long way to go before we can say that these devices truly "speak" the body's language.
As the cost and accessibility of these technologies become more established, they will undoubtedly have a significant impact on healthcare – but also raise questions about who will be able to afford them. Partnerships between public funding agencies and private biotech firms are the result, with prices ranging from £13,000 to £37,000 per prosthetic hand.
While it may seem daunting, one thing is clear: we're at a turning point in human technology. Electronic implants like Prima are not just about restoring sight or mobility; they're about blurring the lines between humans and machines. And that's a future worth embracing.
The new treatment involves surgically implanting a microchip into the retina, which functions as a pattern converter. A camera in a pair of glasses sends visual information to the chip via infrared light, and the chip converts it back into electrical signals that are detected by the retina. The result is astonishing – 84% of patients in a recent trial were able to read letters and numbers with the device, equivalent to an average improvement of about five lines on a standard eye-test chart.
But this is not just a one-off success story; the potential applications of electronic implants are far-reaching. Devices that can read brainwaves are allowing paralysed people to type, while prosthetics currently in trials are controlled by sensors placed on muscles and nerves remaining after amputation, providing users with a sense of touch and proprioception.
The future may seem like science fiction, but it's already here – or at least, it's being developed. Elon Musk's Neuralink venture has taken the lead in direct brain-computer interface technology, implanting a chip into a volunteer's brain to allow basic commands to be sent to a computer.
However, as with any new medical technology, there are risks involved. Adverse events were reported during the macular degeneration trial, including retinal damage requiring further surgery. And even with direct brain implants, there's still a long way to go before we can say that these devices truly "speak" the body's language.
As the cost and accessibility of these technologies become more established, they will undoubtedly have a significant impact on healthcare – but also raise questions about who will be able to afford them. Partnerships between public funding agencies and private biotech firms are the result, with prices ranging from £13,000 to £37,000 per prosthetic hand.
While it may seem daunting, one thing is clear: we're at a turning point in human technology. Electronic implants like Prima are not just about restoring sight or mobility; they're about blurring the lines between humans and machines. And that's a future worth embracing.